In line with our previous work, such treatment enhanced activation of ERK1/2 as well as SYK and BTK following anti-IgM stimulation (Fig. 3B), suggesting that IL4 changes BCR signaling in CLL cells (22). The gene discussed is IL4; the disease is B-cell chronic lymphocytic leukemia.